GSK PLC PE Ratio (TTM) & PE Ratio (TTM) Charts - LSE:GSK

Current and historical daily PE Ratio for GSK PLC ( LSE:GSK ) from 1990 to May 14 2025. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. GSK PLC stock (LSE:GSK) PE ratio as of May 14 2025 is 17.77. More Details

GSK PLC (LSE:GSK) PE Ratio (TTM) Chart

GSK PLC (LSE:GSK) PE Ratio (TTM) Historical Data

View and export this data going back to 1990. Start your Free Trial

Total 1272

GSK PLC PE Ratio (TTM) Historical Data
Date	PE Ratio (TTM) Data	Date	PE Ratio (TTM) Data
2025-05-14	17.8	2025-03-11	24.3
2025-05-12	18.3	2025-03-10	24.9
2025-05-09	18.0	2025-03-07	24.5
2025-05-08	17.9	2025-03-06	24.0
2025-05-07	18.1	2025-03-05	23.7
2025-05-06	19.0	2025-03-04	24.1
2025-05-05	19.0	2025-03-03	23.7
2025-05-02	19.0	2025-02-28	23.5
2025-05-01	19.1	2025-02-27	23.4
2025-04-30	19.4	2025-02-26	23.5
2025-04-29	18.7	2025-02-25	23.7
2025-04-28	18.4	2025-02-24	23.2
2025-04-25	18.2	2025-02-21	22.9
2025-04-24	18.3	2025-02-20	23.1
2025-04-23	18.1	2025-02-19	23.0
2025-04-22	17.8	2025-02-18	23.1
2025-04-21	17.5	2025-02-17	22.7
2025-04-18	17.5	2025-02-14	23.0
2025-04-17	17.5	2025-02-13	23.1
2025-04-16	17.6	2025-02-12	23.1
2025-04-15	17.6	2025-02-11	23.1
2025-04-14	17.3	2025-02-10	23.4
2025-04-11	16.9	2025-02-07	23.1
2025-04-10	16.7	2025-02-06	23.7
2025-04-09	16.5	2025-02-05	23.8
2025-04-08	17.6	2025-02-04	22.1
2025-04-07	17.4	2025-02-03	22.4
2025-04-04	18.6	2025-01-31	22.5
2025-04-03	19.2	2025-01-30	22.4
2025-04-02	18.8	2025-01-29	22.4
2025-04-01	19.2	2025-01-28	22.2
2025-03-31	19.1	2025-01-27	22.4
2025-03-28	19.5	2025-01-24	21.7
2025-03-27	23.6	2025-01-23	21.8
2025-03-26	23.6	2025-01-22	21.7
2025-03-25	23.8	2025-01-21	21.7
2025-03-24	23.8	2025-01-20	21.7
2025-03-21	24.1	2025-01-17	21.7
2025-03-20	24.2	2025-01-16	21.6
2025-03-19	24.1	2025-01-15	21.2
2025-03-18	24.5	2025-01-14	20.7
2025-03-17	24.6	2025-01-13	21.3
2025-03-14	24.2	2025-01-10	21.6
2025-03-13	24.0	2025-01-09	21.6
2025-03-12	23.8	2025-01-08	21.8

GSK PLC (LSE:GSK) PE Ratio (TTM) Comparison

Company	Market Cap(Mil)	PE Ratio (TTM)

Business Description

GSK PLC

NAICS : 325412 SIC : 2834
ISIN : GB00BN7SWP63

https://www.gsk.com

79 New Oxford Street, London, GBR, WC1A 1DG

Compare

LSE:AZNLLYJNJABBVOCSE:NOVO BXSWX:ROGXSWX:NOVNMRKAMGNPFEGILDXPAR:SANBMYTSE:4519TSE:4568SHSE:600276XTER:BAYNTSE:4578BIIBTSE:4503

Traded in other countries / regions

GSK.UKGSK.USAGS71.GermanyGSK1.MexicoGSK.ArgentinaG1SK34.Brazil

Index Membership

STOXX Europe 600 FTSE 100 iShares MSCI ACWI Ex US Index Fund FTSE 100

IPO Date

1972-05-22

Description

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.